Key result
Ultrastructural myofilament changes on electron microscopy predicted mortality and worsening heart failure in dilated cardiomyopathy, whereas patients without changes had only 3 deaths over 4.9 years.
Why the study?
Do ultrastructural cardiomyocyte changes identified by electron microscopy predict mortality and worsening heart failure in patients with newly diagnosed dilated cardiomyopathy?
Do ultrastructural cardiomyocyte changes identified by electron microscopy predict mortality and worsening heart failure in patients with newly diagnosed dilated cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Electron microscopy of endomyocardial biopsies can identify ultrastructural myofilament changes that serve as independent predictors of mortality and worsening heart failure in patients with newly diagnosed dilated cardiomyopathy.
This editorial refers to ‘Ultrastructural features of cardiomyocytes in dilated cardiomyopathy with initially decompensated heart failure as a predictor of prognosis’†, by T. Saito et al., on page 724. Dilated cardiomyopathy (DCM) remains one of the common causes of heart failure, characterized by progressive dilation of the left ventricle and impairment of its function in the absence of significant coronary artery disease. Several causes have been identified that lead to DCM, such as infectious agents, toxins, genetic alterations of myocyte proteins, inflammatory disorders, and peripartum cardiomyopathy. Despite modern therapeutics, DCM is associated with increased morbidity, and mortality remains as high as 20%.1 Risk stratification and identification of the patients at increased risk for progression of heart failure and sudden cardiac death (SCD) remains challenging. Left ventricular ejection fraction (EF) ≤35% and New York Heart Association (NYHA) functional class remain the major prognostic parameters, especially for selection of patients to receive an implantable cardioverter defibrillator (ICD).2 However, EF is not perfect, since many patients with an EF >35% die from SCD and many patients with severely depressed EF never experience arrhythmic death and thus never receive appropriate ICD therapy.3,4 NYHA class is helpful in determining the prognosis of patients with heart failure; however, there is no association between NYHA class and EF.5,6 Furthermore, worsening NYHA class shifts the mode of death from SCD in lower classes to pump failure in higher classes, making it difficult to predict the individual risk.7 Plasma biomarkers such as brain natriuretic peptide (BNP) have been shown to predict the risk of SCD and worsening heart failure; however, trials on BNP-guided treatment of heart failure have shown mixed results till now.8,9 Besides structural parameters such as right ventricular and left atrial size, a promising parameter of prognosis seems to be the identification of late gadolinium enhancement (LGE) as a marker of fibrosis in the midwall of the left ventricle in patients with DCM undergoing cardiovascular magnetic resonance imaging. The presence of fibrosis led to an ∼2.5-fold higher 5-year mortality and was associated with higher risk of SCD, worsening heart failure, and need for cardiac transplantation.10 However, the degree of fibrosis varies greatly among patients with DCM and among different stages of the disease, making it difficult to predict the risk for individuals without the presence of fibrosis.11 The role of endomyocardial biopsy in diagnosis and prognosis of DCM is still a matter of discussion and is meaningful in the setting of myocarditis and differential diagnosis of inflammatory cardiomyopathy. Thus, the presence of inflammation in patients with suspected myocarditis and impaired left ventricular function is predictive of cardiac death or need for transplantation.12 Myocardial viral persistence or the presence of perforin as an inflammatory marker in the endomyocardial biopsy of patients with inflammatory DCM are prognostic for survival or EF improvement.13,14 Different gene expression patterns are helpful in the differential diagnosis of giant cell infiltrates, while distinct microRNA patterns can be used to identify active viral induced inflammation.15,16 Hypertrophy, atrophy, apoptosis, fibrosis, and vascular density are further useful markers for the degree of damage and stage of the disease17 (Figure 1). Endomyocardial biopsy analysings include histology, immunohistology, molecular biolog, and electron microscopy approaches for diagnoses, prognosis, and the development of treatment strategies in dilated cardiomyopathy. Saito et al. report now for the first time the prognostic significance of electron microscopy (EM) analysis of endomyocardial biopsies in patients with DCM.18 In a cohort of 250 patients with first diagnosis of DCM, presenting with acute heart failure, the authors showed that ultructural cardiomyocyte changes were predictive of mortality and worsening heart failure. EM identified three groups of patients showing either no changes in the myofilaments, or changes in the form of focal derangement or diffuse myocyte lysis. Interestingly, the presence of myofilament changes was an independent predictor of all-cause death, cardiac death, and worsening heart failure, with patients showing no changes having an excellent prognosis after the mean follow-up period of 4.9 years (only 3 patients died and 5 patients reached the composite HF endpoint of readmission due to HF or HF death). Notably all groups had the same average EF (range 29–33%) and the same NYHA functional class; however, BNP levels were higher in the patients with myofilament changes. There are some interesting findings in the study. First, both focal derangement and diffuse myofilament lysis were independent predictors of the HF composite endpoint; however, only diffuse myofilament lysis predicted all-cause death. One possible explanation could be that patients with diffuse lysis of myofilaments represent a more advanced DCM stage and therefore sicker patients. Despite the fact that all patients were examined at first presentation, DCM can be asymptomatic for a long time, making the detection of the exact time point when cardiac changes occur difficult.19 Furthermore, previous EM studies in patients with DCM have shown that diffuse myofilament lysis represents a more advanced stage of cellular degeneration and possibly a point where reversible damage to the cardiomyocyte might not be possible any more.20 It would be interesting to see whether the absence of any myofilament changes or focal derangement was also associated with an improvement in LV function, which would provide a strong prognostic factor to guide therapeutic interventions, such as implantation of ICD or cardiac resynchronization therapy (CRT) devices. Secondly, non-cardiac causes of death accounted for 58% of all observed deaths, implying that patients with myofilament changes in the EM tended to die more often from non-cardiac causes, possibly due to existing co-morbidities. Indeed, patients with myofilament changes tended to include more men than women, had more atrial fibrillation, and had lower haemoglobin levels. Thirdly, family history of DCM was a strong predictor of poor prognosis along with myofilament changes. Whether there is an interaction between these changes and genetic causes of DCM or the observed ultrastructural changes are due to different causes is not clear but would be interesting to investigate in future studies. In conclusion, EM could provide important additional prognostic parameters to the existing morphological, histological, and molecular analyses derived from endomyocardial biopsy, important for risk stratification of DCM patients and guiding of their therapy (Figure 1). Future studies need to address the exact role of ultrastructural changes and their therapeutic relevance. However, parameters derived from endomyocardial biopsies together with other markers will bring us one step forward to the direction of personalized medicine in heart failure. Conflict of interest: none declared.
No takes yet. Share an insight, caveat, or question.
Savvatis et al. (2014) conducted an editorial in Dilated cardiomyopathy (n=250). Ultrastructural cardiomyocyte changes on electron microscopy vs. No ultrastructural changes was evaluated on All-cause death, cardiac death, and worsening heart failure. Ultrastructural myofilament changes on electron microscopy predicted mortality and worsening heart failure in dilated cardiomyopathy, whereas patients without changes had only 3 deaths over 4.9 years.
Synapse has enriched 10 related papers. Consider them for comparative context: